Overview

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

Status:
Completed
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.
Phase:
Phase 2
Details
Lead Sponsor:
Philipps University Marburg Medical Center